Moderna's RSV vaccine mRESVIA granted FDA approval to protect ...
The vaccine is already approved in the US for use in adults aged 60 years and older
pmlive.comHere’s a quick update on the latest RSV vaccine news.
- The FDA granted approval for Moderna’s RSV vaccine, mRESVIA, expanding use to younger adults with certain health conditions, with plans to broaden availability for the 2025/2026 season in the US. This follows earlier approvals for older adults (60+) and ongoing evaluations of duration and safety across age groups.[1][2]
- RSV vaccines have also been approved for maternal use to protect newborns, with Pfizer’s Abrysvo targeted at pregnant people in the third trimester; this aims to reduce RSV risk in infants during their first months of life, pending CDC guidance and postmarketing study requirements.[3]
- In the broader landscape, Arexvy (GSK) remains approved for adults 60+ and has shown substantial reductions in RSV-related lower respiratory tract disease and severe outcomes in pivotal trials. Additional safety reviews and guideline updates from the CDC have addressed concerns about rare adverse events, guiding recommendations for different populations.[2][5][9]
Key takeaways by audience
- For older adults: Arexvy and mRESVIA are the primary vaccine options; safety and efficacy data show meaningful protection against RSV-related illness in trial populations, with ongoing surveillance.[5][2]
- For pregnant people and newborns: Abrysvo offers maternal protection to infants through vaccination during late pregnancy; postmarketing studies are required to monitor outcomes, including rare risks.[3]
- For younger adults with health conditions: Moderna’s mRESVIA is expanding eligibility to include some younger adults, reflecting a broader strategy to reduce RSV burden across more age groups.[1]
If you want, I can pull up the most current CDC recommendations for RSV vaccination by age and risk group and summarize any recent safety updates or new regulatory decisions.